NCT00001677View on ClinicalTrials.gov

Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 1998

Study Completion Date

April 30, 2000

Conditions

Arthritis, RheumatoidSynovitis

Interventions

DRUG

Methotrexate

DRUG

Fludarabine

Trial Locations (1)

20892

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda

All Listed Sponsors

lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00001677 - Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy | Biotech Hunter | Biotech Hunter